Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton's tyrosine kina...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2022-06, Vol.6 (11), p.3472-3479
Hauptverfasser:	Phillips, Tycel, Chan, Henry, Tam, Constantine S., Tedeschi, Alessandra, Johnston, Patrick, Oh, Sung Yong, Opat, Stephen, Eom, Hyeon-Seok, Allewelt, Heather, Stern, Jennifer C., Tan, Ziwen, Novotny, William, Huang, Jane, Trotman, Judith
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials and Observations Humans Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, Follicular - drug therapy Piperidines - adverse effects Pyrazoles - adverse effects Pyrimidines - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!